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Introduction: The potential role for vitamin D in infection has beenwell described in adults. The objective
of our study was to determine the prevalence of vitamin D insufﬁciency and to evaluate the relationship
between vitamin D status and markers of innate immunity and infection in critically ill children.
Hypothesis: Vitamin D deﬁciency is highly prevalent in children with critical illness and correlates with
the severity of illness and dysfunction in innate immunity.
Methods: We performed a prospective clinical observational study with both case and control groups in
the pediatric intensive care unit (PICU). Vitamin D status was deﬁned as vitamin D sufﬁcient
(25-hydroxyvitamin D (25(OH)D  20 ng/mL), vitamin D insufﬁcient (25(OH)D 10e20 ng/mL), and
vitamin D deﬁcient (25(OH)D <10 ng/mL). Vitamin D status, severity of illness scores, and cathelicidin,
and other clinical data were collected.
Results: Sixty-one PICU patients and 46 control patients were enrolled. Over 60% of the PICU cases were
found to be vitamin D insufﬁcient while less than 1/3 of the controls were insufﬁcient (p < 0.0001). No
signiﬁcant correlation was seen between plasma 25(OH)D and any severity of illness scores. Cases with
asthma had a signiﬁcantly lower median level 25(OH)D (16.9 ng/mL) than cases without asthma (18.7 ng/
mL). Over 50% of patients hospitalized during the fall and winter were considered vitamin D deﬁcient or
insufﬁcient whereas in the sunnier seasons (spring and summer) the prevalence of vitamin D deﬁciency/
insufﬁciency decreased to about 30% (p ¼ 0.003).
Conclusions: Vitamin D deﬁciency is common in the pediatric critical care population. Signiﬁcant sea-
sonal differences were noted even in the critically ill. The role of vitamin D in certain diseases like asthma
in critically ill children merit further study.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Vitamin D plays an important role, not only for bone health, but
also in the immune system [1]. Both in vitro and clinical studies have
demonstrated that vitaminD is important for the innate and adaptiveBY-NC-ND license (http://
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Inc. Open access under CC BY-NC-ND liceimmune response [2e6]. In adults, vitamin D insufﬁciency is com-
mon in patients who are hospitalized or have a severe infectious
process and is associated with increased mortality [7e11]. Vitamin
D enhances the anti-microbial response of monocytes of adults
suggesting a protective role of vitamin D in infection. Particularly,
anti-microbial peptides such as human cathelicidin antimicrobial
peptide (hCAP18) and b-defensin are up-regulated in response to
vitamin D therapy [12]. In adult patients with sepsis, plasma LL-37,
the active cathelicidin protein cleaved from hCAP18, is positively
correlated to vitamin D status [7,13].
Similar links between vitamin D status and the immune system
have been shown in pediatric populations. For example, children
with cystic ﬁbrosis, who suffer from chronic respiratory infections,
have a high prevalence of vitamin D insufﬁciency that is associated
with increased risk of pulmonary exacerbations [14,15]. Twonse.
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that vitamin D supplementation reduced the risk of inﬂuenza and
recurrent pneumonia [15,16]. Given the potential role of vitamin D
in infection, achieving optimal vitamin D status may be important
in children with infection.
Many children are admitted to a pediatric intensive care unit
(PICU) with serious infections or with a high chance of acquiring
nosocomial infection once admitted [17]. Severe blood stream in-
fections alone account for signiﬁcant morbidity and mortality. Of
the 636,842 patients children admitted to 43 Children’s Hospital
Association (CHA) hospitals between 2004 and 2012 the prevalence
of severe sepsis was 7.7% (49,153) with an associated mortality rate
of 14.4% [18]. Adequate nutritional support has been a mainstay in
pediatric intensive care unit (PICU) management with research
showing improved outcomes and fewer ICU patient days [19].
However, there have been few studies to investigate the prevalence
of vitamin D deﬁciency in critically ill children. Madden et al. found
that 40% of children admitted to the pediatric intensive care unit
had vitamin D deﬁciency [20]. A more recent study found that a
subset of children with pneumonia or bronchiolitis requiring PICU
care had a higher prevalence of vitamin D deﬁciency compared to
children without respiratory symptoms [21]. There may, therefore,
be an important role for vitamin D in the prevention and/or treat-
ment of infections in critically ill children.
The purpose of this study was to examine vitamin D status in
children admitted to our pediatric intensive care unit. We also
evaluated the relationship between vitamin D status andmarkers of
innate immunity and infection. Our hypothesis was that vitamin D
deﬁciency was highly prevalent in children with critical illness and
correlated with the severity of illness and dysfunction in innate
immunity.
Methods
We performed a prospective clinical observational study with
both case and control groups in the pediatric intensive care unit
(PICU) at Children’s Healthcare of Atlanta at Egleston between
January 2010 and March 2012. This study was approved by the
Institutional Review Boards of Emory University and Children’s
Healthcare of Atlanta. Informed consent was obtained from each
patient’s guardian.
PICU and control patient deﬁnition
Patients were recruited from among children 0e18 years of age
with a weight of 6 kg or more admitted to the PICU within the last
48 h. PICU patients were excluded if they had the following issues:
chronic renal disease, gastrointestinal malabsorption conditions,
post-operative state following an elective surgery, or trauma as
related to possible abuse. Control patients were recruited among
children in the magnetic resonance imaging (MRI) suite. Only those
patients undergoing MRI for the following were considered: new
onset headache without other neurological complaint, new onset
seizure without other neurological complaint and not on anti-
epileptic drugs, patients with history of cardiac surgery with four
chamber cardiac anatomy (i.e. VSD, coarctation of the aorta), and
isolated limb complaints without concern for neoplastic or rheu-
matologic condition. Additional inclusion criteria for control pa-
tients were: requirement of intravenous (IV) access for sedation or
contrast, 0e18 years of age, and weight greater than or equal to
6 kg. Controls were excluded if they were on medications, devel-
opmentally delayed, had a severe or chronic illness-deﬁned as any
condition causing signiﬁcant physical or mental disability
(including chronic renal disease), abnormal cardiac anatomy (i.e.
single ventricle physiology), or gastrointestinal malabsorption.Protocol
Blood draws from critically ill children were performed on the
ﬁrst day of enrollment and the ﬁfth day after enrollment to allow
for trending over the time period. Control children only had one
blood draw at the time of enrollment. Patient demographic infor-
mation was obtained from their medical record and included: age,
gender, ethnic group, admission diagnosis, and history of chronic
disease. Clinical information collected included length of hospital
stay, exposure to advance life support systems, duration of me-
chanical ventilation, length of PICU stay (LOS), amount/duration of
medication used, development of rebound hypotension or sec-
ondary infections, and duration of shock.
Determination of severity of illness
Septic shock was deﬁned and classiﬁed according to the
American College of Critical Care Medicine (ACCM) deﬁnitions of
cardiovascular support [22]. Severity of illness scores calculated
were Pediatric Risk of Mortality score III (PRISM III) [23], calculated
risk of mortality, and pediatric logistic organ dysfunction (PELOD)
score [24].
Determination of vitamin D deﬁciency
Vitamin D status was assessed by measurement of plasma 25-
hydroxyvitamin D (25(OH)D). Vitamin D status was deﬁned as
vitamin D sufﬁcient (25(OH)D 20 ng/mL), vitamin D insufﬁcient
(25(OH)D 10e20 ng/mL), and vitamin D deﬁcient (25(OH)D<10 ng/
mL). These categories are consistent with deﬁnitions used to deﬁne
vitamin D status reporting vitamin D status in children partici-
pating in the National Health and Nutrition Examination Survey
(NHANES) [25].
Vitamin D and cathelicidin (LL-37) assays
Blood was collected from case and control patient populations
on the day of enrollment in EDTA tubes. After centrifugation for
plasma separation, plasma was stored at 80 C. Samples were
batch processed for 25(OH)D concentrations using the Immunodi-
agnostic Systems iSYS automated ELISA system (Fountain Hills, AZ).
This method has a lower limit of detection of 4 ng/mL, and corre-
lates well with the gold-standard, liquid chromatography-tandem
mass spectrometry [26]. The laboratory participates in the vit-
amin D external quality assessment scheme (DEQAS) to ensure
accuracy of the measurement of 25(OH)D concentrations, and has a
laboratory inter-assay CV of 10.1e13.0% and intra-assay CV of 1.8e
4.0% for measurement of 25(OH)D. Cathelicidin (LL-37) concentra-
tions were determined in plasma by ELISA (Hycult Biotech, Uden,
Netherlands) as previously reported [27].
Power calculation
Prior to initiating this study, power calculations were performed
using current available data regarding prevalence of vitamin D
deﬁciency [28] and data from several clinical studies that examined
the prevalence of vitamin D deﬁciency in various populations of
hospitalized patients, both adult and pediatric [7,21,29]. In order to
detect a difference of 20% in vitamin D levels between cases and
controls, we calculated a sample size of 50 patients per group was
required to achieve a power of 0.80 using a 2 sided alpha of 0.05. A
convenience sample of 120 patients, 60 patients each for cases and
controls was selected to account for any errors in sample processing
or withdrawal from study participation.
Table 1
Demographics of cases and controls
Variable Level Controls (N ¼ 46) PICU (N ¼ 61) p-Value
Age, mean  SD 7.6  4.5 11.5  5.1 <0.001
Gendera, N (%) Male 16 (45.7%) 34 (56.7%) 0.39
Female 19 (54.3%) 26 (43.3%)
Race, N (%) African American 20 (43.5%) 39 (63.9%) 0.01b
White 22 (47.8%) 16 (26.2%)
Native Hawaiian/Other Paciﬁc Islander 0 (0.0%) 1 (1.6%)
Asian 0 (0.0%) 2 (3.3%)
Multiracial 1 (2.2%) 3 (4.9%)
Other 3 (6.5%) 0 (0%)
Weight (lbs), mean  SD e 45.2  22.7 e
Mechanical ventilation, N (%) Yes e 31 (50.8%) e
PRISM III score, median (IQR) e 10 (7e15) e
Total SOFA, median (IQR) e 7 (2e10) e
Total PELOD, median (IQR) e 20 (7e15) e
Cathelicidin (LL-37)a, median (IQR) 57.8 (35.3e125.9) 56.3 (41.3e79.8) 0.66
25-hydroxyvitamin D (ng/mL)
Mean (SD) 39.6 (21.8) 23.6 (17.0) <0.0001b
Median (IQR) 39.8 (20.1e56.9) 18.5 (12.4e26.8) <0.0001b
Vitamin D status by category Sufﬁcient (20 ng/mL) 35 (76.1%) 24 (39.3%) <0.001b,c
Insufﬁcient (10e20 ng/mL) 11 (23.9%) 27 (44.3%)
Deﬁcient (<10 ng/mL)) 0 (0.0%) 10 (16.4%)
SOFA, Sequential Organ Failure Assessment score; PELOD, Pediatric logistic organ dysfunction; PRISM III, Pediatric Risk of Mortality III.
a Indicates missing data. Data are incomplete for some patients.
b Statistically signiﬁcant differences (p < 0.05).
c p-Value is based on CochraneArmitage test for trend.
Table 2
Comparison of plasma 25-hydroxyvitamin D (ng/mL) between cases and controls
within race groups
Race group Case/Control N Median (IQR) p-Value
Caucasians Control 22 48.0 (22.7e68.2) 0.002
Case 16 20.6 (19.0e25.7)
African Americans Control 20 20.3 (15.2e43.6) 0.12
Case 39 17.1 (10.1e29.7)
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All statistical analyses were performed using SAS 9.2 (Cary, NC).
Statistical signiﬁcance was assessed using a signiﬁcance level of
0.05 unless otherwise noted. Appropriate descriptive statistics (e.g.,
frequencies and percentages, means and standard deviations, or
medians and interquartile ranges) were calculated for cases and
controls. Univariate tests for normality were used to determine if a
parametric test was appropriate. If normality was rejected, a
nonparametric test was used instead. Demographic data for the
healthy controls were compared to PICU patients using t-tests or
Wilcoxon rank sum tests and Chi-square tests. Similar tests were
used to compare plasma 25(OH)D concentrations among subgroups
based on comorbidities such as asthma, septic shock, etc. Plasma
25(OH)D levels were categorized to determine if insufﬁciency was
related to severity of illness, diagnosis, race, or season of hospital
visit. The CochraneArmitage test for trend was used to test for an
association between two ordinal variables (e.g., group and vitamin
D group).
To determine whether plasma 25(OH)D levels were correlated
with severity of illness scores and LL37, Spearman’s rank correlation
and associated 95% conﬁdence intervals were used. The Kruskale
Wallis test was used to determine if severity of illness scores
differed across vitamin D subgroups. To control for multiple com-
parisons, pairwise comparisons between vitamin D subgroupswere
made using a signiﬁcance level of (0.05/4) ¼ 0.0125.
Results
Subject demographics
Sixty-one PICU patients and 46 control patients were enrolled
over a 17-month period. A comparison of demographic character-
istics and lab values between cases and controls can be found in
Table 1. PICU patients were older than controls (11.5 years of age vs.
7.6 years of age; p < 0.001). The distribution of race was not the
same in the two groups (p¼ 0.011); PICU had a higher proportion of
African Americans while the controls had amuch higher proportionof Caucasians (63.9% vs. 43.5%, p ¼ 0.035). There were no gender
differences between the groups (p ¼ 0.40). Table 2 contains the
comparison of plasma 25(OH)D levels between cases and controls
separately for Caucasians and African Americans. There was no
difference in plasma 25(OH)D concentrations between cases and
controls for African Americans; however in the Caucasian subgroup,
cases had a signiﬁcantly lower median plasma 25(OH)D level than
controls (p ¼ 0.002). After adjusting for race, plasma 25(OH)D
concentrations of the cases were signiﬁcantly lower than in the
controls (median; 23.6 vs. 39.8 ng/mL; p < 0.001). When plasma
25(OH)D levels were categorized into sufﬁcient, insufﬁcient, and
deﬁcient, a signiﬁcant association (p < 0.0001) was found between
group (PICU, control) and vitamin D status; over 60% of the PICU
cases were found to be vitamin D insufﬁcient while less than 1/3 of
control were insufﬁcient.Relationship between vitamin D status and markers of critical illness
No signiﬁcant correlations were found between plasma 25(OH)
D and any of the lab values, including the anti-microbial peptide,
LL-37, or between 25(OH)D and any of the severity of illness scores
(Table 3). None of the vitamin D status subgroups were signiﬁcantly
different from one another for any of the severity of illness scores
(Table 4); although, SOFA showed a trend (p ¼ 0.12). Table 5 pro-
vides the median and range of plasma 25(OH)D concentration for
each risk subgroup. Caucasians had the highest median plasma
25(OH)D levels (20.6 ng/mL) followed by African Americans
(17.1 ng/mL) then “other” (16.2 ng/mL). Cases with asthma had a
Table 3
Correlations and associated 95% conﬁdence interval of plasma 25-hydroxyvitamin D concentrations with lab value and severity of illness scores
Outcome Category Variable Groups N Spearman correlation 95% CI LCL 95% CI UCL p-Value
Vitamin D (25(OH)D) Lab values LL37 Cases and Controls 92 0.154 0.054 0.347 0.14
Cases 56 0.115 0.153 0.366 0.40
Controls 36 0.195 0.146 0.490 0.26
Asthma Only 13 0.159 0.649 0.435 0.61
Sepsis only 13 0.302 0.310 0.725 0.32
Severity of illness Total PELOD Cases 61 0.089 0.166 0.333 0.49
PRISM III score Cases 61 0.044 0.210 0.293 0.73
Total SOFA Cases 61 0.219 0.307 0.445 0.09
Total PELOD Asthma only 13 0.172 0.656 0.424 0.58
PRISM III score Asthma only 13 0.088 0.490 0.607 0.78
Total SOFA Asthma only 13 0.208 0.676 0.395 0.50
Total PELOD Sepsis only 15 0.106 0.584 0.432 0.71
PRISM III score Sepsis only 15 0.088 0.572 0.447 0.76
Total SOFA Sepsis only 15 0.014 0.522 0.502 0.96
LL37 Severity of illness Total PELOD Cases 56 0.101 0.354 0.167 0.46
PRISM III score Cases 56 0.111 0.362 0.158 0.42
Total SOFA Cases 56 0.088 0.342 0.180 0.52
Total PELOD Asthma only 13 0.235 0.372 0.691 0.34
PRISM III score Asthma only 13 0.384 0.227 0.765 0.20
Total SOFA Asthma only 13 0.038 0.525 0.576 0.90
Total PELOD Sepsis only 13 0.201 0.672 0.401 0.52
PRISM III score Sepsis only 13 0.061 0.590 0.509 0.85
Total SOFA Sepsis only 13 0.257 0.702 0.352 0.41
SOFA, Sequential Organ Failure Assessment score; PELOD, Pediatric logistic organ dysfunction; PRISM III, Pediatric Risk of Mortality III.
K.B. Hebbar et al. / Journal of Clinical & Translational Endocrinology 1 (2014) 170e175 173signiﬁcantly lower median level plasma 25(OH)D (16.9 ng/mL) than
cases without asthma (18.7 ng/mL). Table 6 contains the compari-
son of race and season between vitamin D subgroups using the
combined sample of cases and controls. Over ﬁfty-percent of pa-
tients hospitalized during the fall and winter were considered
vitamin D deﬁcient or insufﬁcient whereas in the sunnier seasons
(spring and summer) almost 70% of patients were considered
vitamin D sufﬁcient (p ¼ 0.003).Table 5
Comparison of plasma 25-hydroxyvitamin D (ng/mL) levels among risk subgroups in
cases only
Subgroup Level N Median (IQR) p-Value
Race White 16 20.6 (19.0e25.7) 0.01a,bDiscussion
The evolving understanding of vitamin D as an immunomodu-
lator holds great attraction as both a potential target for treatment
and prevention of disease states. In this study, pediatric critical care
patients had a greater burden of vitamin D deﬁciency than healthy
children, with an increased risk among those with asthma. Plasma
25(OH)D levels, however, did not have any direct correlation to
illness severity scoring. Signiﬁcant seasonal variation as well as
ethnic differences in vitamin D was noted in vitamin D status in
these critically ill children.
The association between vitamin D and infections has been
suggested for over a century. Simple observations regarding the
high burden of respiratory infections in children with rickets were
made by medical practitioners of the late 1800s [29]. Additionally,
the placement of tuberculosis patients in sunnier climates to
improve exposure to UV light was noted to improve the clinicalTable 4

















Total PELOD 21.0 (11.0e30.5) 20.0 (1.0e32.0) 11.5 (1.0e30.0) 0.59
PRISM III score 10.5 (7.5e15.5) 10.0 (6.0e15.0) 9.5 (7.0e15.0) 0.89
Total SOFA 8.0 (5.0e10.0) 4.0 (1.0e10.0) 4.5 (1.0e8.0) 0.12
SOFA, Sequential Organ Failure Assessment score; PELOD, Pediatric logistic organ
dysfunction; PRISM III, Pediatric Risk of Mortality III.
a p-Value is from the KruskaleWallis test.state of these patients. These ﬁndings have been revisited in
modern research. Several studies in children have found signiﬁ-
cant associations in between vitamin D deﬁcient states and res-
piratory illness. In a study of pediatric hospital admissions in
Ethiopia, children with clinical evidence of rickets were 13-fold
more likely to present with pneumonia than those without
rickets [29]. In a Canadian study, children admitted to intensive
care for lower respiratory infections had higher rates of vitamin D
deﬁciency [21]. In an adult study, patients with tuberculosis
showed faster response to multi-drug therapy if they were given
vitamin D supplementation [6].
Vitamin D may play an important role in the induction of the
anti-microbial response to pathogens in humans. Macrophages
from vitamin D insufﬁcient persons are not able to optimally up-
regulate production of the active cathelicidin protein, LL-37 [32].
When 25(OH)D is added to vitamin D deﬁcient sera, the production
of LL-37 in response to an infectious signal is restored [5]. In a study
of adults admitted to the ICU, Jeng et al., demonstrated that vitamin
D status positively correlated with plasma LL-37 concentrations [7].
We, however, did not ﬁnd a relationship between vitamin D statusAA 39 17.1 (10.1e29.7)
Other 6 16.2 (13.8e19.2)
Season Spring 12 25.7 (15.2e36.5) 0.09b
Summer 17 20.8 (17.2e33.4)
Fall 8 19.0 (17.7e20.6)
Winter 24 16.4 (9.3e19.3)
Asthmac No 37 18.7 (14.0e24.6) 0.048a
Yes 13 16.9 (9.6e17.7)
Shock No 26 17.5 (11.0e22.0) 0.63
Yes 29 17.3 (12.4e33.4)
Sepsis No 46 18.6 (12.1e26.8) 0.76
Yes 15 18.4 (13.8e29.7)
a Signiﬁcant at 0.05 level of statistical signiﬁcance.
b p-Value obtained from median one-way analysis.
c Indicates missing data.
Table 6
Comparison of vitamin D subgroups with race and season for combined cases and
controls










Race White 29 (76.3%) 9 (23.7%) 0 (0.0%) 0.01b
AA 25 (42.4%) 25 (42.4%) 9 (15.3%)
Other 5 (8.5%) 4 (10.5%) 1 (10.0%)
Season Spring 16 (69.6%) 6 (26.1%) 1 (4.3%) 0.003b,d
Summer 18 (69.2%) 8 (30.8%) 0 (0.0%)
Fall 5 (45.5%) 5 (45.5%) 1 (9.1%)
Winter 20 (40.8%) 19 (38.8%) 10 (20.4%)
Asthmaa,c No 15 (40.5%) 18 (48.7%) 4 (10.8%) 0.02b,d
Yes 1 (7.7%) 8 (61.5%) 4 (30.8%)
Shock and/or
sepsisc
No 11 (35.5%) 16 (51.6%) 4 (12.9%) 0.97d
Yes 13 (43.3%) 11 (36.7%) 6 (20.0%)
a Indicates missing data.
b Signiﬁcant at 0.05 level of statistical signiﬁcance.
c Only for cases.
d p-Value is based on CochraneArmitage test for trend.
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likely reﬂect the heterogeneity of disease of the overall study
population. In a sub-set of patients with sepsis (n ¼ 15) there was
no statistically signiﬁcant relationship between plasma 25(OH)D
and LL-37. It is also possible that blood levels of LL-37 do not
accurately reﬂect the monocyte responses to infection. Adams et al.
demonstrated no change in circulating cathelicidin (hCAP18) con-
centrations in adults receiving oral vitamin D supplementation.
However, the ex vivo harvested and cultured monocytes had
enhanced hCAP18 expression in response to 25-hydroxyvitamin
D. This suggests that enhanced cathelicidin action might only be
detected locally by cells of the immune system. Alternative bio-
markers of innate immunity and markers monocyte action and
function should be explored to determine the impact of vitamin D
on enhancing innate immunity [32].
A prominent ﬁnding was the difference in racial background
between cases and controls. Sixty-four percent of case patients self-
identiﬁed as African-American. This racial distribution was similar
to our general hospital and PICU admissions in the same time
period. The greater representation of African-American cases may
inﬂuence differences in vitamin D status between cases and con-
trols given the well-established fact of greater burden of hypo-
vitaminosis D in the African-American population at large [33,34].
However, our ﬁndings of lower plasma 25(OH)D concentrations in
critically ill pediatric patients remained after adjusting for race.
Recently, it has been suggested that differences in vitamin D status
among black and white Americans may be partially inﬂuenced by
differences in concentration of the vitamin D binding protein and
differences in the frequency of vitamin D binding protein poly-
morphisms [35]. Although African Americans have lower total
25(OH)D concentrations compared to Whites, bioavailable 25(OH)
D concentrations may not differ. Future similar studies in critically
ill pediatric patients should measure vitamin D binding protein and
assess bioavailable 25(OH)D.
Signiﬁcantly lower plasma 25(OH)D levels in critically ill asth-
matic children has been clearly identiﬁed as a subset of patients
worthy of further study. It is well known that there is a signiﬁcant
innate immunologic role in asthma [30,31]. While the mechanisms
for potential beneﬁt to achieve higher plasma 25(OH)D levels is
unclear from this data, further study is certainly warranted in these
children.
One limitation of our study could be our control children. Chil-
dren undergoing sedated MRI are more than likely to have health
complaints indicating the need for scans. The control subjects werecarefully screened for any chronic conditions or suggestion of se-
vere systemic disease before being enrolled. Additional limitations
are PICU patient population is heterogenous in terms of diagnosis
and severity of disease. Where possible we explored high risk
subsets with similar disease processes. As demonstrated, asthma
patients admitted to the ICU had signiﬁcantly poorer vitamin D
status then other patients. This is in line other publications that
demonstrate higher rates of vitamin D deﬁciency in patients
affected by asthma [35,36]. Certainly several arguments exist as to
whether this is an issue of cosegregation of ﬁndings as related to
lifestyle (i.e. asthmatic patients are less active and have decreased
sunlight exposure) or if it may be a contributing factor to the
severity of the illness.
In conclusion, we found a very high prevalence of profound
vitamin D deﬁciency in the pediatric critical care population. In an
era of increasing bacterial antibiotic resistance and limited devel-
opment of new antibiotics, augmentation of immune function by
adjunctive therapies holds great promise for our patients. With re-
gard to chronic inﬂammatory conditions such as asthma, immuno-
modulation beyond current immunosuppressive approaches would
be a great addition. Vitamin D potentially could be developed as a
safe and effective additive therapy in critically ill pediatric patients.
Multicenter trials should be performed to examine the safety,
feasibility, and effectiveness of vitamin D supplementation/repletion
in this at-risk population.References
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